Exact Mass: 495.2696946000001
Exact Mass Matches: 495.2696946000001
Found 115 metabolites which its exact mass value is equals to given mass value 495.2696946000001
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Val Tyr Ser Lys
6-Benzoylheteratisine
C29H37NO6 (495.26207420000003)
Origin: Plant; SubCategory_DNP: Terpenoid alkaloids, Diterpene alkaloid, Aconitum alkaloid
Phe Lys Thr Thr
Phe Thr Lys Thr
Phe Thr Thr Lys
Lys Phe Thr Thr
Lys Ser Val Tyr
Lys Ser Tyr Val
Lys Thr Phe Thr
Lys Thr Thr Phe
Lys Val Ser Tyr
Lys Val Tyr Ser
Lys Tyr Ser Val
Lys Tyr Val Ser
Ser Lys Val Tyr
Ser Lys Tyr Val
Ser Val Lys Tyr
Ser Val Tyr Lys
Ser Tyr Lys Val
Ser Tyr Val Lys
Thr Phe Lys Thr
Thr Phe Thr Lys
Thr Lys Phe Thr
Thr Lys Thr Phe
Thr Thr Phe Lys
Thr Thr Lys Phe
Val Lys Ser Tyr
Val Lys Tyr Ser
Val Ser Lys Tyr
Val Ser Tyr Lys
Val Tyr Lys Ser
Tyr Lys Ser Val
Tyr Lys Val Ser
Tyr Ser Lys Val
Tyr Ser Val Lys
Tyr Val Lys Ser
Tyr Val Ser Lys
(2E,4E,6E,8E)-4,5-dimethoxy-2-nitrobenzyl 3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate
C29H37NO6 (495.26207420000003)
2-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl] Sumatriptan
9-Phenyl-3,6-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole
C30H35B2NO4 (495.2752050000001)
Octanoic acid, 8-oxo-8-(phenylamino)-, [1,8-dioxo-8-(phenylamino)octyl]azanyl ester
C28H37N3O5 (495.27330720000003)
9-phenyl-2,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole
C30H35B2NO4 (495.2752050000001)
(S)-2-(3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-(phenyl(tetrahydro-2H-pyran-4-yl)methyl)-5H-pyrido[3,2-b]indol-7-yl)propan-2-ol
C30H33N5O2 (495.26341180000003)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
Tefinostat
C28H37N3O5 (495.27330720000003)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
[(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-3,4-bis[[tert-butyl(dimethyl)silyl]oxy]oxolan-2-yl]methanol
C22H41N5O4Si2 (495.2696946000001)
N-[(4R,7R,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(5R,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(5S,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(5R,6S,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(5S,6S,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(5R,6R,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(5S,6R,9S)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(4S,7R,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(4S,7S,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(4R,7S,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(5S,6R,9R)-8-(cyclohexylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(4S,7S,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(4R,7R,8R)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(4R,7S,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C25H41N3O5S (495.2766776000001)
N-[(4S,7R,8S)-5-(cyclopentylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]ethanesulfonamide
C25H41N3O5S (495.2766776000001)
[(1S,2S,6S,9S,10R,14R,17S,18S,19S)-12-ethyl-9-hydroxy-17-methoxy-14-methyl-4-oxo-5-oxa-12-azahexacyclo[8.7.2.12,6.01,11.03,9.014,18]icosan-19-yl] benzoate
C29H37NO6 (495.26207420000003)
[(1S,6S,9S,14R,17S,19S)-12-ethyl-9-hydroxy-17-methoxy-14-methyl-4-oxo-5-oxa-12-azahexacyclo[8.7.2.12,6.01,11.03,9.014,18]icosan-19-yl] benzoate
C29H37NO6 (495.26207420000003)
2-amino-3-[[3-[(Z)-hexadec-9-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
C22H42NO9P (495.25970520000004)
[(1S,2S,6S,9S,10R,14R,17S,19S)-12-ethyl-9-hydroxy-17-methoxy-14-methyl-4-oxo-5-oxa-12-azahexacyclo[8.7.2.12,6.01,11.03,9.014,18]icosan-19-yl] benzoate
C29H37NO6 (495.26207420000003)
[(1S,6S,9S,11S,14R,17S,19S)-12-ethyl-9-hydroxy-17-methoxy-14-methyl-4-oxo-5-oxa-12-azahexacyclo[8.7.2.12,6.01,11.03,9.014,18]icosan-19-yl] benzoate
C29H37NO6 (495.26207420000003)
1-(9Z-hexadecenoyl)-glycero-3-phosphoserine
C22H42NO9P (495.25970520000004)
PCSK9-IN-13
C30H33N5O2 (495.26341180000003)
PCSK9-IN-13(compound 3f) is a potent PCSK9 inhibitor, which can antagonize low-density lipoprotein (LDL) receptor binding by binding to PCSK9, with an IC50 of 537 nM[1].
5,13,18-trihydroxy-16-[(2-hydroxyphenyl)methyl]-9,15-dimethyl-14-methylidene-5h,6h,7h,8h,9h,10h,12ah,13h,15h,15ah,16h-oxacyclotetradeca[2,3-d]isoindol-2-one
C29H37NO6 (495.26207420000003)
(1r,14r,16s,20s,21s,22r)-21,22-dihydroxy-5,8-dimethoxy-24-azapentacyclo[14.7.1.1²,⁶.1⁷,¹¹.0²⁰,²⁴]hexacosa-2,4,6(26),7(25),8,10-hexaen-14-yl acetate
C29H37NO6 (495.26207420000003)
n-{[(8e)-3,11-dimethyl-19-methylidene-7,13-dioxo-6,21-dioxabicyclo[15.3.1]henicosa-2,8,10,14-tetraen-5-yl](hydroxy)methyl}hexa-2,4-dienimidic acid
C29H37NO6 (495.26207420000003)
5,13,18-trihydroxy-16-[(4-hydroxyphenyl)methyl]-9,15-dimethyl-14-methylidene-5h,6h,7h,8h,9h,10h,12ah,13h,15h,15ah,16h-oxacyclotetradeca[2,3-d]isoindol-2-one
C29H37NO6 (495.26207420000003)
(4e)-n-[(s)-[(1s,2e,5s,14e,17s)-3,11-dimethyl-19-methylidene-7,13-dioxo-6,21-dioxabicyclo[15.3.1]henicosa-2,8,10,14-tetraen-5-yl](hydroxy)methyl]hexa-2,4-dienimidic acid
C29H37NO6 (495.26207420000003)
benzoyl heteratisine
C29H37NO6 (495.26207420000003)
{"Ingredient_id": "HBIN017817","Ingredient_name": "benzoyl heteratisine","Alias": "benzoylheteratisine","Ingredient_formula": "C29H37NO6","Ingredient_Smile": "CCN1CC2(CCC(C34C2C(C(C31)C5(CCC6CC4C5C(=O)O6)O)OC(=O)C7=CC=CC=C7)OC)C","Ingredient_weight": "0","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "24392;2243","TCMSP_id": "NA","TCM_ID_id": "6368","PubChem_id": "NA","DrugBank_id": "NA"}
(1s,4e,6r,10r,12e,14r,15s,17r,18s,19s,20s)-20-benzyl-6,15,22-trihydroxy-10,17,18-trimethyl-2,16-dioxa-21-azatetracyclo[12.8.0.0¹,¹⁹.0¹⁵,¹⁷]docosa-4,12,21-trien-3-one
C29H37NO6 (495.26207420000003)
(5r,9r,12as,13s,15s,15as,16s,18as)-5,13,18-trihydroxy-16-[(2-hydroxyphenyl)methyl]-9,15-dimethyl-14-methylidene-5h,6h,7h,8h,9h,10h,12ah,13h,15h,15ah,16h-oxacyclotetradeca[2,3-d]isoindol-2-one
C29H37NO6 (495.26207420000003)
21,22-dihydroxy-5,8-dimethoxy-24-azapentacyclo[14.7.1.1²,⁶.1⁷,¹¹.0²⁰,²⁴]hexacosa-2,4,6(26),7(25),8,10-hexaen-14-yl acetate
C29H37NO6 (495.26207420000003)
(2z,4e)-n-[(r)-[(1r,2e,5r,8e,10z,14e,17r)-3,11-dimethyl-19-methylidene-7,13-dioxo-6,21-dioxabicyclo[15.3.1]henicosa-2,8,10,14-tetraen-5-yl](hydroxy)methyl]hexa-2,4-dienimidic acid
C29H37NO6 (495.26207420000003)
20-benzyl-6,15,22-trihydroxy-10,17,18-trimethyl-2,16-dioxa-21-azatetracyclo[12.8.0.0¹,¹⁹.0¹⁵,¹⁷]docosa-4,12,21-trien-3-one
C29H37NO6 (495.26207420000003)
(2s)-2-{[(2s)-1-hydroxy-2-[(1-hydroxy-3-methylbutylidene)amino]-3-(4-hydroxyphenyl)propylidene]amino}-3-methyl-n-[(2s)-1-oxo-3-phenylpropan-2-yl]butanimidic acid
C28H37N3O5 (495.27330720000003)
2-({1-hydroxy-2-[(1-hydroxy-3-methylbutylidene)amino]-3-(4-hydroxyphenyl)propylidene}amino)-3-methyl-n-(1-oxo-3-phenylpropan-2-yl)butanimidic acid
C28H37N3O5 (495.27330720000003)
(1s,6s,9s,10r,14r,17s,19s)-12-ethyl-9-hydroxy-17-methoxy-14-methyl-4-oxo-5-oxa-12-azahexacyclo[8.7.2.1²,⁶.0¹,¹¹.0³,⁹.0¹⁴,¹⁸]icosan-19-yl benzoate
C29H37NO6 (495.26207420000003)
(5r,9r,12as,13s,15s,15as,16s,18as)-5,13,18-trihydroxy-16-[(4-hydroxyphenyl)methyl]-9,15-dimethyl-14-methylidene-5h,6h,7h,8h,9h,10h,12ah,13h,15h,15ah,16h-oxacyclotetradeca[2,3-d]isoindol-2-one
C29H37NO6 (495.26207420000003)
(2z,4e)-n-[(s)-[(1s,2z,5s,8z,10z,14z,17s)-3,11-dimethyl-19-methylidene-7,13-dioxo-6,21-dioxabicyclo[15.3.1]henicosa-2,8,10,14-tetraen-5-yl](hydroxy)methyl]hexa-2,4-dienimidic acid
C29H37NO6 (495.26207420000003)
(2z,4e)-n-[(s)-[(1s,2e,5s,8e,10z,14e,17s)-3,11-dimethyl-19-methylidene-7,13-dioxo-6,21-dioxabicyclo[15.3.1]henicosa-2,8,10,14-tetraen-5-yl](hydroxy)methyl]hexa-2,4-dienimidic acid
C29H37NO6 (495.26207420000003)
3-[1,4,7,10-tetrahydroxy-6-isopropyl-13-oxo-3-(sec-butyl)-3h,6h,9h,12h,15h,16h,17h,17ah-pyrrolo[1,2-a]1,4,7,10,13-pentaazacyclopentadecan-9-yl]propanoic acid
(2s,3s)-2-{[(2s)-1-hydroxy-2-[(1-hydroxy-3-methylbutylidene)amino]-3-(4-hydroxyphenyl)propylidene]amino}-n-[(2s)-1-hydroxy-4-(methylsulfanyl)butan-2-yl]-3-methylpentanimidic acid
C25H41N3O5S (495.2766776000001)
3-[(3s,6s,9s,17ar)-3-[(2s)-butan-2-yl]-1,4,7,10-tetrahydroxy-6-isopropyl-13-oxo-3h,6h,9h,12h,15h,16h,17h,17ah-pyrrolo[1,2-a]1,4,7,10,13-pentaazacyclopentadecan-9-yl]propanoic acid
(5r,9r,12ar,13s,15s,15ar,16s,18as)-5,13,18-trihydroxy-16-[(2-hydroxyphenyl)methyl]-9,15-dimethyl-14-methylidene-5h,6h,7h,8h,9h,10h,12ah,13h,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one
C29H37NO6 (495.26207420000003)
2-({1-hydroxy-2-[(1-hydroxy-3-methylbutylidene)amino]-3-(4-hydroxyphenyl)propylidene}amino)-n-[1-hydroxy-4-(methylsulfanyl)butan-2-yl]-3-methylpentanimidic acid
C25H41N3O5S (495.2766776000001)
(1s,14r,16r,20r,21s,22s)-21,22-dihydroxy-5,8-dimethoxy-24-azapentacyclo[14.7.1.1²,⁶.1⁷,¹¹.0²⁰,²⁴]hexacosa-2,4,6(26),7(25),8,10-hexaen-14-yl acetate
C29H37NO6 (495.26207420000003)
(2s)-2-{[(2r)-1-hydroxy-2-[(1-hydroxy-3-methylbutylidene)amino]-3-(4-hydroxyphenyl)propylidene]amino}-3-methyl-n-[(2r)-1-oxo-3-phenylpropan-2-yl]butanimidic acid
C28H37N3O5 (495.27330720000003)